# Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

> **NCT01069965** · PHASE2 · TERMINATED · sponsor: **N-Gene Research Laboratories, Inc.** · enrollment: 196 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** BGP-15 100 mg QD
- **DRUG:** BGP-15 100 mg BID
- **DRUG:** Placebo BID
- **DRUG:** BGP-15 200 mg QD
- **DRUG:** BGP-15 200 mg BID
- **DRUG:** BGP-15 400 mg QD

## Key facts

- **NCT ID:** NCT01069965
- **Lead sponsor:** N-Gene Research Laboratories, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2011-08
- **Final completion:** 2011-10
- **Target enrollment:** 196 (ACTUAL)
- **Why stopped:** Funding support withdrawn.
- **Last updated:** 2014-09-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01069965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01069965, "Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01069965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*